As shown in Fig. 1A, PARD3 expression was significantly higher in cholangiocarcinoma (CHOL), Diffuse large B-cell lymphoma (DLBC), glioblastoma (GBM), kidney renal papillary cell carcinoma (KIRP), low-grade glioma (LGG), liver hepatocellular carcinoma (LIHC), lung adenocarcinoma (LUAD), lung squamous cell carcinoma (LUSC), pancreatic adenocarcinoma (PAAD), stomach adenocarcinoma (STAD), testicular germ cell tumor (TGCT) and thymic carcinoma (THYM). This evidence concerns the gene PARD3 and thymoma.